Print Friendly, PDF & Email

NCT/Study#

NCT03601078 /

BB2121-MM-002

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2)

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: